Skip to main content
. 2020 Aug 15;222(12):1965–1973. doi: 10.1093/infdis/jiaa508

Figure 5.

Figure 5.

Depletion of receptor-binding domain (RBD)–binding antibodies only partially lowers angiotensin-converting enzyme 2 (ACE2)–trimer inhibition. A, B, Plasma samples from 3 coronavirus disease 2019 (COVID-19)–positive and 1 control individual were depleted of RBD-binding (A) or trimer-binding I (B) immunoglobulins by incubation with 3 rounds of RBD- or trimer-conjugated carboxy-modified latex (CML) beads. After each round, a sample was removed and assayed for remaining anti-RBD (A) or anti-trimer immunoglobulin G (IgG) (B). C, COVID-19–positive, not-depleted plasma inhibited trimer-ACE2 binding. Anti-RBD-depleted plasma was less efficient at inhibiting trimer-ACE2 binding, although the difference was not significant by analysis of variance (ANOVA). Anti-trimer–depleted plasma showed a significantly reduced ability to inhibit ACE2-trimer binding, with the mean overlapping with control levels (ANOVA F[2,6] = 8.51, P = .02, not depleted vs RBD depleted P = .11, not significant [NS]; not depleted vs trimer depleted). *P = .02; RBD depleted vs trimer depleted P = .30 by Tukey post hoc test.